Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer

Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic

Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 08 Prague, Czech Republic

⁴

Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic

⁵

Department of Medical Genetics, Centre for Medical Genetics and Reproductive Medicine, Gennet, 170 00 Prague, Czech Republic

⁶

Department of Medical Genetics, AGEL Laboratories, AGEL Research and Training Institute, 741 01 Novy Jicin, Czech Republic

⁷

Department of Medical Genetics, GHC Genetics, 110 00 Prague, Czech Republic

⁸

Department of Medical Genetics, Pronatal, 147 00 Prague, Czech Republic

⁹

Department of Medical Genetics, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic

¹⁰

Research Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12808 Prague, Czech Republic

¹¹

Department of Gynecology and Obstetrics, Hospital Na Bulovce and First Faculty of Medicine, Charles University, 180 81 Prague, Czech Republic

¹²

Laboratory of Cancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, 142 20 Prague, Czech Republic

Show full affiliation list

Hide full affiliation list

Author to whom correspondence should be addressed.

Cancers 2020, 12(4), 956; https://doi.org/10.3390/cancers12040956

Received: 15 March 2020 / Revised: 7 April 2020 / Accepted: 10 April 2020 / Published: 13 April 2020

(This article belongs to the Special Issue Molecular Genetics of Breast and Ovary Cancer)

View Full-Text Download PDF

Browse Figures

Review Reports Citation Export

Abstract

Ovarian cancer (OC) is the deadliest gynecologic malignancy with a substantial proportion of hereditary cases and a frequent association with breast cancer (BC). Genetic testing facilitates treatment and preventive strategies reducing OC mortality in mutation carriers. However, the prevalence of germline mutations varies among populations and many rarely mutated OC predisposition genes remain to be identified. We aimed to analyze 219 genes in 1333 Czech OC patients and 2278 population-matched controls using next-generation sequencing. We revealed germline mutations in 18 OC/BC predisposition genes in 32.0% of patients and in 2.5% of controls. Mutations in BRCA1/BRCA2, RAD51C/RAD51D, BARD1, and mismatch repair genes conferred high OC risk (OR > 5). Mutations in BRIP1 and NBN were associated with moderate risk (both OR = 3.5). BRCA1/2 mutations dominated in almost all clinicopathological subgroups including sporadic borderline tumors of ovary (BTO). Analysis of remaining 201 genes revealed somatic mosaics in PPM1D and germline mutations in SHPRH and NAT1 associating with a high/moderate OC risk significantly; however, further studies are warranted to delineate their contribution to OC development in other populations. Our findings demonstrate the high proportion of patients with hereditary OC in Slavic population justifying genetic testing in all patients with OC, including BTO. View Full-Text

Keywords: ovarian cancer; next-generation sequencing; predisposition genes; cancer risk; mutation

▼ Show Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

Supplementary File 1:
PDF-Document (PDF, 379 KiB)

Share and Cite

MDPI and ACS Style

Lhotova, K.; Stolarova, L.; Zemankova, P.; Vocka, M.; Janatova, M.; Borecka, M.; Cerna, M.; Jelinkova, S.; Kral, J.; Volkova, Z.; Urbanova, M.; Kleiblova, P.; Machackova, E.; Foretova, L.; Hazova, J.; Vasickova, P.; Lhota, F.; Koudova, M.; Cerna, L.; Tavandzis, S.; Indrakova, J.; Hruskova, L.; Kosarova, M.; Vrtel, R.; Stranecky, V.; Kmoch, S.; Zikan, M.; Macurek, L.; Kleibl, Z.; Soukupova, J. Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer. Cancers 2020, 12, 956. https://doi.org/10.3390/cancers12040956

AMA Style

Lhotova K, Stolarova L, Zemankova P, Vocka M, Janatova M, Borecka M, Cerna M, Jelinkova S, Kral J, Volkova Z, Urbanova M, Kleiblova P, Machackova E, Foretova L, Hazova J, Vasickova P, Lhota F, Koudova M, Cerna L, Tavandzis S, Indrakova J, Hruskova L, Kosarova M, Vrtel R, Stranecky V, Kmoch S, Zikan M, Macurek L, Kleibl Z, Soukupova J. Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer. Cancers. 2020; 12(4):956. https://doi.org/10.3390/cancers12040956

Chicago/Turabian Style

Lhotova, Klara, Lenka Stolarova, Petra Zemankova, Michal Vocka, Marketa Janatova, Marianna Borecka, Marta Cerna, Sandra Jelinkova, Jan Kral, Zuzana Volkova, Marketa Urbanova, Petra Kleiblova, Eva Machackova, Lenka Foretova, Jana Hazova, Petra Vasickova, Filip Lhota, Monika Koudova, Leona Cerna, Spiros Tavandzis, Jana Indrakova, Lucie Hruskova, Marcela Kosarova, Radek Vrtel, Viktor Stranecky, Stanislav Kmoch, Michal Zikan, Libor Macurek, Zdenek Kleibl, and Jana Soukupova. 2020. "Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer" Cancers 12, no. 4: 956. https://doi.org/10.3390/cancers12040956

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer

Abstract

Supplementary Material

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI